Eye implant offers new hope

Article

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

The CentraSight treatment programme features a small telescope implant for patients with binocular end stage AMD. This treatment has, until now, only been available in the US and is the only surgical option that has been clinically proven to improve visual quality and quality in life for patients at this stage of the disease.

Mr Ahmed El-Amir, consultant ophthalmologist at Spire Dunedin, Reading, UK, was the first surgeon to perform the procedure in the UK. “I am very pleased to be able to offer my patients this revolutionary treatment, which is a true paradigm shift for patients with untreatable, advanced AMD who have had, up to now, very limited options in improving their quality of life,” he said.

Another surgeon who has recently performed a CentraSight procedure, Mr Nick Wilson-Holt (Duchy Hospital, Truro, UK) added, “CentraSight is a clinical programme that is very carefully targeted only to suitable patients who will potentially gain visual acuity from the procedure. It is not a cure for end-stage AMD, but it allows patients to use the undamaged part of their central retina to be able to see or discern objects using portions of their central vision once more.”

More detailed information about the procedure and its availability may be found on the website.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.